The UK says mixing vaccines against Kovid-19 is not recommended

The UK says mixing vaccines against Kovid-19 is not recommended

Mary Ramsay, head of immunization at Public Health England (PHE), said on Saturday (2) that it is not recommended to mix different vaccines against Kovid-19, and that the first option should always be the same vaccine dose. . Same patient. In some cases, application of different doses of the vaccine to the same patient is better than not giving a second dose for lack of the same vaccine, the statement said after an agency document.

This text, published on Thursday (31), acknowledges that there is no evidence on the reciprocity of vaccination. In this, the organ states that in cases of incomplete immunization, in which a vaccinated person fails, for some reason, to receive a second dose in the correct period, the vaccination must be resumed using the same vaccination, but the first Without repeating the dose.

See also

However, in cases where the person does not try to vaccinate or where he or she wants to be vaccinated, there is not a single vaccine at the location, then it is “reasonable” to get the product that is available accordingly. . Document.

“This option is preferable if the person is likely to be exposed to a high risk immediately or in the face of the conclusion that he or she is unlikely to return to seek health care,” the document states. “Under these conditions, since both vaccines are based on the virus S protein (Spike), the second dose is likely to help increase the response to the first.”

In a statement released today, the PHE chief stated that “there may be extremely rare occasions” when the vaccine given in the first dose is not available for the second dose. “Every effort should be made to ensure that patients receive the same vaccine, but where this is not possible, it is better to give a second dose of another vaccine than any dose.”

READ  Bow crane collapse: 4 wounded and folks trapped


Currently, two vaccines are authorized for emergency use of Pfizer in partnership with Bioentech and AstraZeneca in partnership with the University of Oxford in the United Kingdom. Both use proteins from viruses as a basis, but the first uses the technique of so-called messenger RNA (mRNA), and the second, chimpanzee adenovirus.

Cory Weinberg

About the author: Cory Weinberg

Cory Weinberg covers the intersection of tech and cities. That means digging into how startups and big tech companies are trying to reshape real estate, transportation, urban planning, and travel. Previously, he reported on Bay Area housing and commercial real estate for the San Francisco Business Times. He received a "best young journalist" award from the National Association of Real Estate Editors.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *